Business Context and Reporting Period
This Form 8-K Current Report was filed by Supernus Pharmaceuticals, Inc. on October 9, 2023. The report details a specific corporate event regarding the company's drug development pipeline rather than a standard financial reporting period.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a current report on a specific event and does not contain financial statements or performance metrics.
Material Changes
The primary material event reported is the resubmission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA). Specifically:
- Product: SPN-830 (apomorphine infusion device).
- Indication: Continuous treatment of motor fluctuations (OFF episodes) in Parkinson's disease.
- Action: Resubmission of the NDA on October 9, 2023.
Guidance, Outlook, and Risks
The filing contains forward-looking statements regarding the company's plans and strategies but explicitly states that the company undertakes no obligation to update these statements. The document references various risks and uncertainties, including:
- Ordinary business operations and general economic conditions.
- Market competition.
- Risk factors detailed in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2022.
Investor Verification Checklist
- Verify the status of the resubmitted NDA for SPN-830 with the FDA.
- Review the full text of the press release (Exhibit 99.1) for specific details on the resubmission rationale.
- Consult the most recent Form 10-K or 10-Q for current financial health, cash runway, and debt levels, as this 8-K does not contain such data.
- Monitor future filings for FDA responses or decisions regarding the SPN-830 application.